Influence of serum vitamin D level in the response of actinic keratosis to ingenol mebutate.
actinic keratosis
ingenol mebutate
vitamin D
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
09
10
2022
received:
10
08
2022
accepted:
16
10
2022
pubmed:
20
10
2022
medline:
21
12
2022
entrez:
19
10
2022
Statut:
ppublish
Résumé
Vitamin D (VD) serum levels, and keratinocytic basal expression of vitamin D receptor (VDR) before treatment of actinic keratoses (AK) have been previously reported as possible biomarkers of the response of AK to treatments. We intended to evaluate the association between these and other serum and immunohistochemical parameters with the response of AK to treatment with topical ingenol mebutate (IM). Twenty-five patients with AK on the head were treated with topical IM 0.015% gel once daily for 3 days. Biopsies were taken at baseline and 6 weeks after treatment. Immunohistochemical staining was performed for VDR, P53, Ki67, Aurora B, Survivin and β-catenin. Basal serum 25(OH)D levels were determined. IM was more effective for KIN I and II AKs than in KIN III, and histological responders showed significantly higher serum VD levels (30.278 [SD 8.839] ng/mL) than nonresponders (21.14 [SD 7.079] ng/mL, p = 0.023). In addition, mean basal expression of VDR (45.63 [SD 16.105] %) increased significantly (57.92 [SD 14.738] %, p = 0.003) after treatment with IM. A significant decrease after treatment in the expression of several markers of aggressiveness and progression to squamous cell carcinoma, namely P53, Ki-67, aurora B kinase and survivin, was also observed. Our results support a relationship between VD status and the response of AK to treatment with topical IM, suggesting that its previous correction to proper serum levels in VD-deficient patients could improve the response of AK to the treatment.
Substances chimiques
3-ingenyl angelate
0
Diterpenes
0
Survivin
0
Tumor Suppressor Protein p53
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15949Subventions
Organisme : Instituto de Salud Carlos III
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : FIS PI18/00708
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
European Medicines Agency. EMA review of Picato concludes medicine's risks outweigh its benefits. Accessed May 07, 2020. https://www.ema.europa.eu/en/news/emareview-picato-concludes-medicines-risks-outweigh-its-benefits.
Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys. 2012;523(1):123-133.
Bickle D. The vitamin D receptor: a tumor suppressor in skin. Discov Med. 2011;11:7-17.
Kamradt J, Rafi L, Mitschele T, et al. Analysis of the vitamin D system in cutaneous malignancies. Recent Results Cancer Res. 2003;164:259-269.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019.
Moreno Romero J, Campoy A, Perez N, Garcia F, Grimalt R. Rapidly-growing squamous cell carcinoma shortly after treatment with ingenol mebutate for actinic keratoses: report of two cases. Br J Dermatol. 2015;173(6):1514-1517.
Maglie R, Grandi V, Maio V, Pileri A. Squamous cell carcinoma developed after ingenol mebutate therapy: a possible consequence of the treatment? G Ital Dermatol Venereol. 2018;153(3):442-443.
Ehret M, Velter C, Tebacher M, Bruant-Rodier C, Cribier B. Carcinome épidermoïde de croissance rapide après traitement par mébutate d'ingénol. Ann Dermatol Vénéréologie. 2018;145(10):607-612.
Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017;177(2):350-358.
Grandi V, di Gennaro P, Torrigiani S, Basco L, Lastrucci I, Pimpinelli N. Ingenol mebutate-mediated reduction in p53-positive keratinocytes in skin cancerization field directly correlates with clinical response in patients with multiple actinic keratoses. J Eur Acad Dermatol Venereol. 2019;33(7):1297-1303.
Bobyr I, Campanati A, Consales V, et al. Ingenol mebutate in actinic keratosis: a clinical, videodermoscopic and immunohistochemical study. J Eur Acad Dermatol Venereol. 2017;31(2):260-266.
Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol. 1990;1(3):199-206.
Bagazgoitia L, Cuevas Santos J, Juarranz A, Jaén P. Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers. Br J Dermatol. 2011;165(1):144-151.
Gracia-Cazaña T, Mascaraque M, Lucena SR, et al. Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy. PloS One. 2019;14(4):e0215537.
Gracia-Cazaña T, Salazar N, Vera-Álvarez J, et al. Clinical, histological and immunohistochemical markers of resistance to methyl aminolaevulinate photodynamic therapy in Bowen disease. Br J Dermatol. 2018;178(2):e138-e140.
Dallaglio K, Petrachi T, Marconi A, et al. Expression of nuclear survivin in normal skin and squamous cell carcinoma: a possible role in tumour invasion. Br J Cancer. 2014;110(1):199-207.
Ahmed A, Shamsi A, Mohammad T, Hasan GM, Islam A, Hassan MI. Aurora B kinase: a potential drug target for cancer therapy. J Cancer Res Clin Oncol. 2021;147(8):2187-2198.
Moreno R, Nájera L, Mascaraque M, Juarranz Á, González S, Gilaberte Y. Influence of serum vitamin D level in the response of actinic keratosis to photodynamic therapy with methylaminolevulinate. J Clin Med. 2020;9(2):E398.
Reichrath J, Reichrath S, Heyne K, Vogt T, Roemer K. Tumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling. Front Physiol. 2014;5:166.
Bikle DD, Jiang Y. The protective role of vitamin d signaling in non-melanoma skin cancer. Cancer. 2013;5(4):1426-1438.
Bikle DD. The vitamin D receptor as tumor suppressor in skin. Adv Exp Med Biol. 2020;1268:285-306.